To match the growing demand for biopharmaceutical development and manufacturing, Catalent Biologics has invested extensively in its network to create a comprehensive end-to-end offering for its customers.
To match the growing demand for biopharmaceutical development and manufacturing, Catalent Biologics has invested extensively in its network to create a comprehensive end-to-end offering for customers that includes cell line development, analytical testing, clinical and commercial biomanufacturing, antibody-drug conjugate (ADC) development, fill-finish, and clinical supply services.
The acquisition and integration of Cook Pharmica, LLC’s Bloomington, Indiana facility into Catalent Biologics’ network has strengthened the company’s position as a leader in clinical and commercial-scale biomanufacturing and finished product supply. The acquisition adds expertise in fill/finish liquid and lyophilised vials, prefilled syringes, and cartridges, secondary packaging, including auto-injectors and safety devices, and 2,500 litres of biomanufacturing capacity.
In addition to the Bloomington site, Catalent Biologics’ network includes a state-of-the-art development and manufacturing facility in Madison, Wisconsin; SMARTag® ADC technology in Emeryville, California, prefilled syringe services in Brussels, Belgium; and a network of biologics analytical labs and clinical supply sites around the globe.
Investment and expansion has recently been undertaken at the Madison facility to accommodate two new, 2,000 litre single-use bioreactor systems, enabling late-phase clinical and commercial production of up to 4,000 litre batches. Analytical and process development laboratories at the site have also been expanded to meet greater capacity and capabilities.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.